- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| ASPIRE BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| Do | Aspire Biopharma Holdings, Inc.: Aspire Biopharma's Subsidiary Announces Agreement with TruLife Distribution to Drive National Retail Expansion | 174 | ACCESS Newswire | Agreement Set to Expand BUZZ BOMB Distribution Across Natural, Specialty, and Mass Merchandiser Channels ESTERO, FL / ACCESS Newswire / March 19, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP)... ► Artikel lesen | |
| Di | Aspire Biopharma Holdings, Inc.: Aspire Biopharma's Subsidiary, Buzz Bomb Caffeine Company, Appoints John Choe as Western Sales Director | 534 | ACCESS Newswire | ESTERO, FL / ACCESS Newswire / March 17, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire"), wholly owned subsidiary, Buzz Bomb Caffeine Company, has appointed 25-year industry veteran... ► Artikel lesen | |
| 12.03. | Aspire Biopharma Holdings, Inc.: Aspire Biopharma's Subsidiary to Feature BUZZ BOMB at The Health & Fitness Show 2026 | 226 | ACCESS Newswire | ESTERO, FL / ACCESS Newswire / March 12, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire"), wholly owned subsidiary, Buzz Bomb Caffeine Company, announces its participation at The Health... ► Artikel lesen | |
| 10.03. | Aspire Biopharma Holdings, Inc.: Aspire Biopharma's BUZZ BOMB Disrupts Energy Category with New Convenience Store Pack | 302 | ACCESS Newswire | Convenient Size at the Convenience Store ESTERO, FL / ACCESS Newswire / March 10, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire"), today announced that its subsidiary, Buzz Bomb Caffeine... ► Artikel lesen | |
| 04.03. | Aspire Biopharma and Microsize collaborate for alprazolam powder formulation | 3 | Pharmaceutical Technology | ||
| 03.03. | Aspire Biopharma Holdings, Inc.: Aspire Biopharma Partners with Microsize to Develop Rapid-delivery Sublingual Powder Formulation of Alprazolam for Faster Anxiety Relief | 286 | ACCESS Newswire | Collaboration aims to create the first-ever sublingual alprazolam powder, addressing the need for faster-acting anxiety medication.Phase 1 clinical trial of the patent-pending, rapid-onset formulation... ► Artikel lesen | |
| 25.02. | Aspire Biopharma Holdings, Inc.: Aspire Biopharma's Buzz Bomb Caffeine Company Achieves Record Social Media Growth and Sales Surge Following World-Record Marathon Sponsorship | 312 | ACCESS Newswire | BUZZ BOMB captures over 400,000 views and a spike in online revenue driven by strategic brand expansion and Ashley Paulson's historic record at the Jackpot Ultra Running Festival. ESTERO, FL / ACCESS... ► Artikel lesen | |
| 20.02. | Aspire Biopharma regains Nasdaq compliance requirements | 1 | Investing.com | ||
| 20.02. | Aspire Biopharma Holdings, Inc.: Aspire Biopharma Regains Full Compliance with Nasdaq Listing Requirements | 308 | ACCESS Newswire | Company achieves minimum stockholders' equity rule; Nasdaq confirms matter is closedAspire maintains listing on the Nasdaq ESTERO, FL / ACCESS Newswire / February 20, 2026 / Aspire Biopharma Holdings... ► Artikel lesen | |
| 19.02. | Aspire Biopharma Holdings, Inc.: Aspire Biopharma's Buzz Bomb Caffeine Company Names ChicExecs as Public Relations Agency of Record | 296 | ACCESS Newswire | ESTERO, FL / ACCESS Newswire / February 19, 2026 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company") today announced that its wholly owned subsidiary Buzz Bomb Caffeine Company... ► Artikel lesen | |
| 17.02. | Aspire Biopharma files patent for rapid-relief meclizine formulation | 3 | Investing.com | ||
| 17.02. | Aspire Biopharma meldet Patent für schnell wirkende Meclizin-Formulierung an | 2 | Investing.com Deutsch | ||
| 17.02. | Aspire Biopharma Holdings, Inc.: Aspire Biopharma Files Provisional Patent Application for a Fast-Acting Sublingual Powder Formulation of Meclizine | 317 | ACCESS Newswire | New delivery system targets rapid-onset relief for motion sickness and vertigo, modernizing the $450M global market for the active ingredient in Dramamine.Meclizine was the top-prescribed antiemetic/antivertigo... ► Artikel lesen | |
| 13.02. | Aspire Biopharma appoints Phillip Balatsos to board of directors | 3 | Investing.com | ||
| 13.02. | Aspire Biopharma Holdings, Inc.: Aspire Biopharma Announces the Appointment of New Member to Its Board of Directors | 402 | ACCESS Newswire | New independent director Phillip Balatsos brings commercial and capital markets expertise to drive development patent-pending drug delivery platform ESTERO, FL / ACCESS Newswire / February 13, 2026... ► Artikel lesen | |
| 12.02. | Aspire Biopharma Holdings, Inc.: Aspire Biopharma Files Provisional Patent Application for a Fast-Acting Sublingual Powder Formulation of Ondansetron | 350 | ACCESS Newswire | New sublingual delivery system designed to provide more rapid relief from nausea caused by cancer medicinesOndansetron, currently sold under the brand name Zofran, was the 53rd most commonly prescribed... ► Artikel lesen | |
| 11.02. | Aspire Biopharma secures up to $21M in convertible preferred stock financing | 4 | Seeking Alpha | ||
| 11.02. | Aspire Biopharma Holdings, Inc.: Aspire Biopharma Announces $21 Million Private Placement by Select Investors, Strengthening Balance Sheet, Capital Position, and Fortifying Shareholder Equity to Meet Nasdaq Requirements | 371 | ACCESS Newswire | ESTERO, FLORIDA / ACCESS Newswire / February 11, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), a biopharmaceutical company developing multi-faceted patent-pending... ► Artikel lesen | |
| 10.02. | Aspire Biopharma regains Nasdaq minimum bid price compliance | 2 | Seeking Alpha | ||
| 10.02. | Aspire Biopharma Holdings, Inc.: Aspire Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement | 245 | ACCESS Newswire | Company achieves minimum $1.00 closing bid for 10 consecutive business days; Nasdaq confirms matter is closed ESTERO, FLORIDA / ACCESS Newswire / February 10, 2026 / Aspire Biopharma Holdings, Inc.... ► Artikel lesen |
1 2 3 4 5 Weiter >>
86 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| APTORUM GROUP | 1,060 | +13,98 % | Aptorum Group Ltd: Aptorum Group Limited Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency | Hong Kong, March 06, 2026 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM), a leading Biotechnology company, today announced that it has received a notification from the Nasdaq Stock Market... ► Artikel lesen | |
| CHINA HEALTH GROUP INC | 0,005 | 0,00 % | C HEALTH GP (08225): NOTICE OF BOARD MEETING | ||
| BAYER | 38,385 | -0,21 % | Aktien Frankfurt Ausblick: Stabilisierung - Unicredit bietet für Commerzbank | FRANKFURT (dpa-AFX) - Der Dax dürfte recht stabil in den elften Handelstag seit Kriegsausbruch im Iran starten. Der X-Dax signalisierte für den deutschen Leitindex rund eine Stunde vor Handelsbeginn... ► Artikel lesen | |
| MERCK KGAA | 104,05 | -3,07 % | JPMORGAN stuft MERCK KGAA auf 'Overweight' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Merck KGaA mit einem Kursziel von 150 Euro auf "Overweight" belassen. Nach den Quartalszahlen des Pharma- und Spezialchemiekonzerns... ► Artikel lesen | |
| INHIBIKASE THERAPEUTICS | 1,800 | -2,17 % | Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension | Phase 3 Study initiating in First Quarter of 2026 Single Pivotal Study Accelerates Potential FDA Approval Timeline by Approximately 3 Years BOSTON and ATLANTA, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Inhibikase... ► Artikel lesen | |
| NOVO NORDISK | 31,560 | 0,00 % | HV-Termine: Hauptversammlungen bei All for One, BB Biotech, MeVis, Novo Nordisk, Sartorius | Einmal jährlich müssen sich Aufsichtsrat und Vorstand einer Gesellschaft den Aktionären stellen: Die Hauptversammlung ist das höchste Organ einer Aktiengesellschaft und vergleichbarer Unternehmens-Formen.... ► Artikel lesen | |
| PFIZER | 23,315 | +0,15 % | 3 Charts in 3x33 Sekunden - Heute mit DAX, Palo Alto und Pfizer | 3 Charts in 3x33 Sekunden - Heute mit DAX, Palo Alto und Pfize ► Artikel lesen | |
| SANOFI | 76,88 | +0,05 % | BERENBERG stuft SANOFI auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat Sanofi mit einem Kursziel von 105 Euro auf "Buy" belassen. Die Zurückhaltung der Anleger vor der Strategievorstellung des neuen Chefs bremse... ► Artikel lesen | |
| GSK | 22,470 | -0,71 % | BARCLAYS stuft GSK auf 'Underweight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat die Einstufung für GSK mit einem Kursziel von 1900 Pence auf "Underweight" belassen. Jüngste Absatzdaten belegten auf Wochensicht... ► Artikel lesen | |
| SCHOTT PHARMA | 12,960 | -1,97 % | SCHOTT PHARMA AG & CO KGAA im strukturellen Gleichgewicht | ||
| ELI LILLY | 782,30 | -0,29 % | Stammzelltherapien erreichen den Markt - Mesoblast neben Eli Lilly und Novartis im Fokus | ||
| DERMAPHARM | 40,900 | -0,73 % | Ihre wichtigsten Termine: Nvidia, Qualcomm, Audi, Dermapharm, Docusign und Fraport stehen heute im Fokus! | Gut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine 07:00 Uhr, Deutschland: Fraport... ► Artikel lesen | |
| ETON PHARMACEUTICALS | 22,250 | +7,13 % | Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results | Q4 2025 product sales of $21.3 million, representing 83% growth over Q4 2024Q4 2025 basic GAAP EPS of $0.06, fully diluted GAAP EPS of $0.05, basic non-GAAP EPS of $0.21, fully diluted non-GAAP EPS... ► Artikel lesen | |
| NOVARTIS | 126,24 | +0,27 % | Notable healthcare headlines for the week: Eli Lilly, Novo Nordisk, and Novartis in focus | ||
| ABBVIE | 178,80 | +0,56 % | Defensive Biotech-Wetten? Warum Amgen und AbbVie strukturell wachsen - kleiner Player Mesoblast im Fokus |
Das Unternehmen ASPIRE BIOPHARMA HOLDINGS INC kann der Branche Pharma zugeordnet werden. Die relative Kursveränderung beträgt aktuell +11,51 % bei einem Aktienkurs von 0,707 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ASPIRE BIOPHARMA HOLDINGS INC finden Sie auf Wallstreet Online.